Literature DB >> 30298748

Beneficial Effects of Korean Red Ginseng in the Progression of Non-Alcoholic Steatohepatitis via FABP4 Modulation.

Hyeneui Jeong1, Jong-Won Kim1, Myeon-Sik Yang1, Chul Park1, Jong Hoon Kim1, Chae Woong Lim1, Bumseok Kim1.   

Abstract

Korean red ginseng (KRG) is a traditional herbal medicine used to prevent several geriatric diseases due to its therapeutic effects on metabolic disorder, including type 2 diabetes and fatty liver disease. In this study, we investigated the effects of KRG on the progression of nonalcoholic steatohepatitis (NASH) in mice. NASH was induced by feeding a methionine- and choline-deficient high-fat or high-fat/high-sucrose diet for 6 or 13 weeks, respectively. Each diet group was also orally administered saline (group G0) or KRG extract (100, 200, or 400 mg/kg/day; groups G1, G2, and G4, respectively). KRG showed anti-inflammatory and antifibrogenic effects in the diet-induced NASH models. Furthermore, the expression levels of lipid metabolism-related genes were markedly decreased with KRG treatment in both diet-induced NASH groups. We next confirmed the expression levels of FABP4 in the liver and its ability to regulate inflammation and/or oxidative stress. We observed decreased levels of FABP4 mRNA and protein in the KRG-treated groups indicating that KRG affects the pathogenesis of NASH-related inflammatory responses by modulating FABP4 expression. Results of in vitro experiments showed similar patterns in cells treated with KRG, indicating that KRG treatment regulates the expression of FABP4 and subsequently reduces NASH related inflammation. Our findings suggest a novel role of KRG in NASH-related inflammatory responses via modulation of FABP4 expression in the liver. KRG may be a safe alternative therapy to prevent NASH progression.

Entities:  

Keywords:  FABP4; Ginseng; Liver; Mice; Nonalcoholic Steatohepatitis

Year:  2018        PMID: 30298748     DOI: 10.1142/S0192415X18500817

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  6 in total

1.  Oleate acid-stimulated HMMR expression by CEBPα is associated with nonalcoholic steatohepatitis and hepatocellular carcinoma.

Authors:  Deyu Zhang; Jiahong Liu; Tian Xie; Qiwei Jiang; Lihua Ding; Jianhua Zhu; Qinong Ye
Journal:  Int J Biol Sci       Date:  2020-08-27       Impact factor: 6.580

2.  The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model.

Authors:  Linfu Liu; Chuang Liu; Manyu Zhao; Qianru Zhang; Ying Lu; Ping Liu; Hua Yang; Jinliang Yang; Xiaoxin Chen; Yuqin Yao
Journal:  PLoS One       Date:  2020-12-16       Impact factor: 3.240

3.  Effect of Korea red ginseng on nonalcoholic fatty liver disease: an association of gut microbiota with liver function.

Authors:  Ji Taek Hong; Min-Jung Lee; Sang Jun Yoon; Seok Pyo Shin; Chang Seok Bang; Gwang Ho Baik; Dong Joon Kim; Gi Soo Youn; Min Jea Shin; Young Lim Ham; Ki Tae Suk; Bong-Soo Kim
Journal:  J Ginseng Res       Date:  2020-07-16       Impact factor: 6.060

4.  Attenuation of Perfluorooctane Sulfonate-Induced Steatohepatitis by Grape Seed Proanthocyanidin Extract in Mice.

Authors:  Tao Huang; Yurong Zhang; Wenjuan Zhang; Tingting Lin; Luoting Chen; Bei Yang; Lei Wu; Jianhua Yang; Dalei Zhang
Journal:  Biomed Res Int       Date:  2020-12-09       Impact factor: 3.411

5.  Hepatic Lipidomics and Molecular Imaging in a Murine Non-Alcoholic Fatty Liver Disease Model: Insights into Molecular Mechanisms.

Authors:  Ricardo Rodríguez-Calvo; Sara Samino; Josefa Girona; Neus Martínez-Micaelo; Pere Ràfols; María García-Altares; Sandra Guaita-Esteruelas; Alexandra Junza; Mercedes Heras; Oscar Yanes; Xavier Correig; Lluis Masana
Journal:  Biomolecules       Date:  2020-09-03

Review 6.  Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease.

Authors:  Juan Moreno-Vedia; Josefa Girona; Daiana Ibarretxe; Lluís Masana; Ricardo Rodríguez-Calvo
Journal:  Biomedicines       Date:  2022-01-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.